Xiamen Innovax Biotech Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2005-03-28
- Employees
- -
- Market Cap
- -
- Website
- http://www.innovax.cn
A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ
Completed
- Conditions
- Autoimmune DiseasesAdverse Pregnancy Outcomes
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 1322084
- Registration Number
- NCT06824896
- Locations
- 🇨🇳
Xiamen Innovax Biotech Co., Ltd, Xiamen, Fujian, China
Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above
Phase 4
Completed
- Conditions
- Hepatitis E
- Interventions
- Biological: Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 612
- Registration Number
- NCT06564116
- Locations
- 🇨🇳
Youxi County Center for Disease Control and Prevention, Sanming, Fujian, China
Immunogenicity and Safety of One Dose of HPV Vaccine
Phase 4
Completed
- Conditions
- Human Papillomavirus Vaccines
- Interventions
- Biological: HPV vaccine
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06345885
- Locations
- 🇨🇳
Fujian Provincial Center for Disease Control and Prevention, Fuzhou, Fujian, China
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Phase 4
Completed
- Conditions
- Cervical Intraepithelial NeoplasiaVaginal Intraepithelial NeoplasiaCervical CancerVulvar Intraepithelial NeoplasiaPersistent Infection
- Interventions
- Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT05426148
- Locations
- 🇨🇳
Dongtai City Center for Disease Control and Prevention Dongtai, Jiangsu, Dongtai, Jiangsu, China
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
Phase 4
- Conditions
- Human Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18Hepatitis E Virus Infection
- Interventions
- Biological: CecolinBiological: Hecolin
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 480
- Registration Number
- NCT05415345
- Locations
- 🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hanzhou, Zhejiang, China
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
Phase 4
Completed
- Conditions
- Hepatitis E
- Interventions
- Biological: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- First Posted Date
- 2017-12-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT03365921
- Locations
- 🇨🇳
Dongtai City Center for Disease Control and Prevention, Dongtai, Jiangsu, China
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
Phase 4
Completed
- Conditions
- Hepatitis E
- Interventions
- Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 125
- Registration Number
- NCT03168412
- Locations
- 🇨🇳
Changshan Center for Disease Control and Prevention, Quzhou, Zhejiang, China
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
Phase 4
Completed
- Conditions
- Hepatitis E
- Interventions
- Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 475
- Registration Number
- NCT02964910
- Locations
- 🇨🇳
Rushan Center for Disease Control and Prevention, Weihai, Shandong, China
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
Phase 4
Completed
- Conditions
- Hepatitis BHepatitis E
- Interventions
- Biological: HEV vaccineBiological: HBV vaccine
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 602
- Registration Number
- NCT02584543
- Locations
- 🇨🇳
Beijing Chaoyang District CDC, Beijing, Beijing, China
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
Phase 4
Completed
- Conditions
- Hepatitis E
- Interventions
- Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT02417597
- Locations
- 🇨🇳
Kaihua Center for Disease Control and Prevention, Quzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath